Inositol supplementation and body mass index: A systematic review and meta‐analysis of randomized clinical trials

Abstract

Background: Inositol is a sugar-alcohol and recognized as a key component of cell membrane phospholipids. It has crucial role in the cell signaling pathways and contribute to improving glycemic responses. Although some earlier studies have revealed the effect of inositol mediating glucose uptake by improving insulin sensitivity, the benefit of inositol supplementation in patients with overweight and obesity is not completely understood. This study aimed to assess the impact of inositol supplementation on body mass index (BMI) through a systematic review and meta-analysis of controlled clinical trials. Methods:A systematic search was performed to August 2021 in the following databases: PubMed-Medline, Embase, Web of Science and Scopus. Fifteen controlled clinical trials investigating the effect of inositol on adult's BMI were finally included in the study. A random-effects model was employed to estimate the effect size.Subgroup analysis was performed by dose, duration, age, type of inositol. Metaregression was used to investigate presence of any linear relationship. Begg's and Egger's tests were carried out to detect small study effect. Results:The results of pooled analysis showed that inositol supplementation significantly decreased BMI scores (WMD = −0.41 kg/m 2 ; 95% CI: −0.78, −0.04; p = 0.028). Subgroup analysis was performed to identify the source of heterogeneity among studies (I 2 = 73.9%, p < 0.001), demonstrating supplementation duration, baseline BMI, mean age of participants, type of inositol and dosage were potential Meysam Zareadeh and Azadeh Dehghani have contributed equally to this work and share first authorship.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Does myo‐inositol supplementation influence oxidative stress biomarkers in patients with non‐alcoholic fatty liver disease?

“…This finding is consistent with the results of previous studies (Fruzzetti et al, 2017;Pintaudi et al, 2016). For example, showed that inositol supplementation significantly reduced BMI (Zarezadeh et al, 2022). In diabetic rats, supplementation with inositol derivatives, especially inositol hexaphosphate (IP6), resulted in weight reduction through increasing serum leptin, which in turn regulated food intake (Foster et al, 2016).…”

“…Several studies have reported the effectiveness of DCI and MI in improving obesity-related complications in patients with PCOS and metabolic syndrome (Giordano et al, 2011;Unfer et al, 2016;Zheng et al, 2015) diets, dietary supplements, and exercise. The beneficial effect of inositol on obesity and related disorders may be explained by its involvement in insulin signaling and improving insulin sensitivity (Zarezadeh et al, 2022). However, the short duration of the trial and the difference in the type of disease in the studied population are also involved in inconsistent findings.…”

“…reported a significant reduction in weight and BMI in adolescents after 3 months (Pkhaladze et al., 2021 ). Moreover, the results of a meta‐analysis including 15 controlled clinical trials showed that inositol supplementation significantly reduced BMI (Zarezadeh et al., 2022 ). In diabetic rats, supplementation with inositol derivatives, especially inositol hexaphosphate (IP6), resulted in weight reduction through increasing serum leptin, which in turn regulated food intake (Foster et al., 2016 ).…”

Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels

“…In the present study, metformin/myo-inositol combination therapy, but not metformin alone, tended to reduce BMI. This observation is in line with the results of a recent meta-analysis of 15 controlled clinical trials [ 22 ]. The authors reported that oral inositol supplementation reduced BMI and that this effect was particularly pronounced in people over 40 years of age.…”

Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease

“…NC is also linked to metabolic disorders such as CVD and atherosclerosis as well as influenced by changes in insulin levels ( 29 ). A recent meta-analysis reported not only the beneficial effects of INSs on BMI reduction but also a stronger association of MI with BMI reduction compared to other derivatives of INS ( 30 ). Moreover, SBP was significantly reduced in the MI group compared to the placebo group ( p = 0.006), while no significant inter-group difference was observed in DBP ( Table 2 ).…”